Antares Pharma'a Otrexup NDA accepted by FDA Antares Pharma announced that the New Drug Application for Otrexup, a potential new product for the subcutaneous delivery of methotrexate using Medi-Jet technology, has been accepted by the FDA indicating that the application is sufficiently complete to permit a substantive review. Otrexup is being developed for self-administration of MTX to enhance the treatment of rheumatoid arthritis, poly-articular-course juvenile RA and psoriasis. The FDA has assigned a target date of October 14, ten months from the official NDA filing, to complete its review of the NDA.
News For ATRS From The Last 14 Days
Check below for free stories on ATRS the last two weeks.